MJ Potter, CC Claudio, SM Szabo - British Medical Journal, 2009 - bjo.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Cited by 1 - Related articles - All 3 versions
MJ Potter, CC Claudio, SM Szabo - bjo.bmj.com Page 1. doi: 10.1136/bjo.2008.155531 published online June 10, 2009 Br J Ophthalmol
Michael J Potter, Cheryl C Claudio and Shelagh M Szabo ... Related articles
[CITATION] PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in …
GA Lalwani, PJ Rosenfeld, AE Fung, SR … - American Journal of Ophthalmology, 2009 - Elsevier In this open-label, prospective, single-center, uncontrolled clinical study, AMD
patients with neovascularization involving the central fovea and a central
retinal thickness (CRT) of at least 300 μm as measured by OCT were ... Cited by 5 - Related articles - All 23 versions
- ►duanessolution.com S Sacu, A Varga, S Michels, G Weigert, K … - British Medical Journal, 2008 - bjo.bmj.com Results: Baseline characteristics were well balanced in both groups (p>0.05). At
week 12, patients in group A had a mean loss of −3.7 letters compared with a
gain of 3.4 letters in group B (p = 0.04, between both groups). Both ... Cited by 5 - Related articles - All 5 versions
- ►prsjournal.com TA Ciulla, PJ Rosenfeld - Current Opinion in Ophthalmology, 2009 - journals.lww.com Recent findings: Two anti-VEGF agents, pegaptanib sodium and ranibizumab, are
currently approved by the United States Food and Drug Administration for the
treatment of neovascular AMD. In addition, off-label use of a third ... Cited by 7 - Related articles - All 5 versions
PK Kaiser - Ophthalmology, 2009 - Elsevier Retrospective analysis of baseline data with ongoing follow-up. Physicians from
45 clinical centers entered patient data at baseline and follow-up examinations,
including subsequent treatments, into a secure, Web-accessed database. ... Cited by 2 - Related articles
FB Aggio, GB Melo, AL Höfling-Lima, FM Eid - Acta Ophthalmologica Scandinavica, 2006 - ncbi.nlm.nih.gov 1: Acta Ophthalmol Scand. 2006 Dec;84(6):831-3. Photodynamic therapy with
verteporfin combined with intravitreal injection of bevacizumab ... Cited by 9 - Related articles - BL Direct - All 3 versions
MR Barakat, PK Kaiser - Expert Opinion on Investigational Drugs, 2009 - Informa Pharma Science Age-related macular degeneration (AMD) is the leading cause of blindness in the
Western world for those patients aged 50 years or older. Neovascular AMD, a
subtype characterized by the growth of new, pathologic blood vessels, ... Cited by 3 - Related articles - All 6 versions
- ►duanessolution.com CG Kiss, C Simader, S Michels, U Schmidt- … - British Journal of Ophthalmology, 2008 - bjo.bmj.com Results: Over 9 months, seven patients gained three to 24 letters and one had
unchanged VA. Three patients lost eight to 24 letters due to recurrence and
received another verteporfin treatment at month 6. Median retinal ... Cited by 4 - Related articles - All 6 versions
